EPISODE · Jun 24, 2025 · 11 MIN
Oxford, UK based Pathios Therapeutics is targeting GPR65 for cancer, a signaling pathway that becomes active in the low pH tumor microenvironment and causes immunosuppression and high angiogenesis
from BiotechTV - News · host BiotechTV
CEO Paul Higham describes the biology of GPR65 inhibition, something that pharma companies have previously tried to do, and explains how cancer patients who genetically have low signaling are seen to have better outcomes in than other genotypes.
What this episode covers
CEO Paul Higham describes the biology of GPR65 inhibition, something that pharma companies have previously tried to do, and explains how cancer patients who genetically have low signaling are seen to have better outcomes in than other genotypes.
NOW PLAYING
Oxford, UK based Pathios Therapeutics is targeting GPR65 for cancer, a signaling pathway that becomes active in the low pH tumor microenvironment and causes immunosuppression and high angiogenesis
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.